GSA Capital Partners LLP decreased its position in shares of Bio-Techne Corp (NASDAQ:TECH) by 82.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,800 shares of the biotechnology company’s stock after selling 26,800 shares during the quarter. GSA Capital Partners LLP’s holdings in Bio-Techne Corp were worth $682,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Eaton Vance Management raised its holdings in Bio-Techne Corp by 0.4% during the 2nd quarter. Eaton Vance Management now owns 2,566 shares of the biotechnology company’s stock worth $302,000 after purchasing an additional 9 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in Bio-Techne Corp by 0.5% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 3,664 shares of the biotechnology company’s stock worth $372,000 after purchasing an additional 20 shares during the last quarter. Capstone Asset Management Co. raised its holdings in Bio-Techne Corp by 0.4% during the 2nd quarter. Capstone Asset Management Co. now owns 7,680 shares of the biotechnology company’s stock worth $902,000 after purchasing an additional 30 shares during the last quarter. State of Wisconsin Investment Board raised its holdings in Bio-Techne Corp by 0.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 7,392 shares of the biotechnology company’s stock worth $869,000 after purchasing an additional 50 shares during the last quarter. Finally, American Capital Management Inc. raised its holdings in Bio-Techne Corp by 1.1% during the 2nd quarter. American Capital Management Inc. now owns 9,470 shares of the biotechnology company’s stock worth $1,113,000 after purchasing an additional 105 shares during the last quarter. Hedge funds and other institutional investors own 98.41% of the company’s stock.

In related news, Director Karen A. Holbrook sold 1,059 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $121.73, for a total transaction of $128,912.07. Following the completion of the transaction, the director now owns 914 shares in the company, valued at $111,261.22. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 1,359 shares of company stock valued at $164,122. 3.40% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/07/gsa-capital-partners-llp-has-682000-holdings-in-bio-techne-corp-tech.html.

Shares of Bio-Techne Corp (TECH) opened at 122.56 on Friday. The firm has a market cap of $4.58 billion, a P/E ratio of 60.37 and a beta of 0.76. The stock’s 50 day moving average is $121.26 and its 200 day moving average is $113.53. Bio-Techne Corp has a 12 month low of $95.68 and a 12 month high of $124.00.

Bio-Techne Corp (NASDAQ:TECH) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.10. The company had revenue of $156.60 million during the quarter, compared to the consensus estimate of $150.25 million. Bio-Techne Corp had a return on equity of 14.19% and a net margin of 12.93%. The firm’s revenue for the quarter was up 16.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.92 earnings per share. Equities research analysts expect that Bio-Techne Corp will post $3.99 EPS for the current year.

Several research firms have issued reports on TECH. Deutsche Bank AG set a $132.00 price target on shares of Bio-Techne Corp and gave the stock a “buy” rating in a report on Wednesday, August 30th. BidaskClub upgraded shares of Bio-Techne Corp from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Zacks Investment Research lowered shares of Bio-Techne Corp from a “buy” rating to a “hold” rating in a report on Tuesday, August 15th. Finally, Wells Fargo & Company began coverage on shares of Bio-Techne Corp in a report on Thursday, July 13th. They set a “market perform” rating for the company. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $127.50.

Bio-Techne Corp Company Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH).

Institutional Ownership by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Stock Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related stocks with our FREE daily email newsletter.